A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.
dc.contributor.author | Ford, Ian | |
dc.contributor.author | Blauw, Gerard Jan | |
dc.contributor.author | Murphy, Michael B | |
dc.contributor.author | Shepherd, James | |
dc.contributor.author | Cobbe, Stuart M | |
dc.contributor.author | Bollen, Edward LEM | |
dc.contributor.author | Buckley, Brendan M | |
dc.contributor.author | Jukema, J Wouter | |
dc.contributor.author | Hyland, Michael | |
dc.contributor.author | Gaw, Allan | |
dc.contributor.author | Lagaay, A Margot | |
dc.contributor.author | Perry, Ivan J | |
dc.contributor.author | Macfarlane, Peter | |
dc.contributor.author | Norrie, John | |
dc.contributor.author | Meinders, A Edo | |
dc.contributor.author | Sweeney, Brian J | |
dc.contributor.author | Packard, Chris J | |
dc.contributor.author | Westendorp, Rudi GJ | |
dc.contributor.author | Twomey, Cillian | |
dc.contributor.author | Stott, David J | |
dc.date.accessioned | 2010-04-06T10:15:02Z | |
dc.date.available | 2010-04-06T10:15:02Z | |
dc.date.issued | 2002-05-20 | |
dc.identifier.citation | A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics. 2002, 3 (1):8 Curr Control Trials Cardiovasc Med | en |
dc.identifier.issn | 1468-6694 | |
dc.identifier.pmid | 12097148 | |
dc.identifier.doi | 10.1186/1468-6708-3-8 | |
dc.identifier.uri | http://hdl.handle.net/10147/95637 | |
dc.description.abstract | BACKGROUND: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. METHODS: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition. RESULTS: In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0-9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women). CONCLUSIONS: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002. | |
dc.language | ENG | |
dc.title | A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics. | en |
dc.contributor.department | University of Glasgow, Scotland. ian@stats.gla.ac.uk | en |
dc.identifier.journal | Current controlled trials in cardiovascular medicine | en |
refterms.dateFOA | 2018-09-03T10:43:52Z | |
html.description.abstract | BACKGROUND: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. METHODS: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition. RESULTS: In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0-9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women). CONCLUSIONS: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002. |